drugset / Trial / NCT00523380
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy. Patients will be treated for 6 months.
Timeline
- Start
- 2007-10-04
- Primary completion
- 2009-01-07
- Completion
- 2009-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | recombinant interleukin-21 | Protein / enzyme biologic | — | Intravenous |